Gimatecan is a semi-synthetic lipophilic camptothecin analogue classified as a topoisomerase I inhibitor, currently researched for its potential in treating glioma and various solid tumors. This category… Read more
Gimatecan is a semi-synthetic lipophilic camptothecin analogue classified as a topoisomerase I inhibitor, currently researched for its potential in treating glioma and various solid tumors. This category provides essential pharmaceutical reference standards required for the rigorous analytical testing and quality control of this active pharmaceutical ingredient. Laboratories utilize these high-quality materials, including specific impurity standards and stable isotope labelled compounds like Gimatecan-d9 and deuterated impurities, to support precise impurity profiling and accurate quantification in complex matrices. By incorporating these validated reference materials into liquid chromatography-mass spectrometry (LC-MS) methods, researchers can ensure robust method validation and compliance with regulatory standards throughout the drug development lifecycle. These compounds are indispensable for detecting and quantifying trace-level degradation products and metabolites, ultimately ensuring the safety and efficacy of Gimatecan-based formulations during stability testing and routine analysis.